eFT226

Phase 2Small molecule

EEffector Therapeutics

eFT226 is one of 11 small molecule programs targeting Solid Tumor Malignancies. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid Tumor MalignanciesRecruiting

Solid Tumor MalignanciesPhase 2

Recruiting

Competition

Competitive Landscape

17 competitors in Solid Tumor Malignancies

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

3 2

Opdivo

Bristol-Myers Squibb

Phase 3

2 3

Herceptin

Roche

Phase 2

2 4

Lumakras

Amgen

Phase 2

1 5

Verzenio

Eli Lilly

Phase 2

1 6

Taxotere

AAvyxa

Phase 2

1 7

Faslodex

FFresenius Kabi USA, LLC

Phase 2

1 8

GV20-0251

GGV20 Therapeutics

Phase 2

2 9

KB707

KKrystal Biotech, Inc.

Phase 2

1 10

eFT226

EEffector Therapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Solid Tumor Malignancies1 trial

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

Recruiting·EEffector Therapeutics·Phase 1/2·NCT04092673·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for eFT226. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — eFT226 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for eFT226. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Effector Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEffector Therapeutics

eFT226

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Solid Tumor Malignancies1 trial

References

Drug Info

Quick Facts

Related News